Noninvasive Ventilation Bundle in Postoperative Respiratory Failure

NACompletedINTERVENTIONAL
Enrollment

158

Participants

Timeline

Start Date

January 31, 2013

Primary Completion Date

October 31, 2014

Study Completion Date

November 30, 2014

Conditions
Respiratory Insufficiency
Interventions
OTHER

Early application of NIV

"Device:BiPAP Vision.~NIV bundle group : Early application of NIV(BiPAP Vision) in 1 h after randomization."

DEVICE

Fiberoptic bronchoscopy

Device:fiberoptic bronchoscopy. NIV bundle group :When patients were inability to spontaneously clear airways from excessive secretions during NIV, fiberoptic bronchoscopy (FBO) was used for suction of secretions.

DRUG

Propofol

"Drug:propofol.continuous perfusion of propofol (0.50-2.00 mg/kg/h).~NIV bundle group :When patients showed intolerance or inadequate patient cooperation during the NIV session, they were sedated (Ramsay scale 2-3) by a continuous perfusion of propofol (0.50-2.00 mg/kg/h).~In the conventional treatment group: No intervention."

OTHER

Conventional application of NIV

Conventional treatment group:NIV(BiPAP Vision) was used, when patients failed the supplemental oxygen and met at least two of the following criteria:(1) severe respiratory distress with dyspnoea, respiratory rate\>30breaths/min, and clinical signs suggestive of respiratory-muscle fatigue or increased respiratory effort (use of accessory respiratory muscles or paradoxical abdominal breathing, or intercostal indrawing), (2) respiratory acidosis (arterial pH of 7.35 or less with PaCO2 of 45 mm Hg or more) ;(3) arterial O2 saturation by pulse oximetry less than 90% or PaO2 less than 60 mm Hg at an FiO2\> 0.5 or breathing at least 10 L/min oxygen.

Trial Locations (1)

610041

Department of Critical care medicine of West China Hospital, Chengdu

All Listed Sponsors
lead

West China Hospital

OTHER

NCT02214368 - Noninvasive Ventilation Bundle in Postoperative Respiratory Failure | Biotech Hunter | Biotech Hunter